Author

S. C. Baca

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Approach:experimental assay· 5 Research Focus:cell type annotation· 4 Approach:statistical model· 4 Assay:ChIP-seq· 3 Research Focus:chromatin & epigenetic regulation· 3 Research Focus:differential expression· 3 Research Focus:cancer & tumor microenvironment· 2

Frequent Co-Authors

M. L. Freedman· 6 shared E. Corey· 3 shared A. D. Choudhury· 2 shared C. Giambartolomei· 2 shared C. Morrissey· 2 shared H. M. Nguyen· 2 shared J. E. Berchuck· 2 shared J.-H. Seo· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

M. L. Freedman

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Mechanism for controlled assembly of transcriptional condensates by Aire

Y.-S. Huoh, Q. Zhang, R. Torner, S. C. Baca, H. Arthanari, S. Hur

This paper identifies a multi-layered mechanism by which Aire forms transcriptional condensates on enhancers through coordinated interactions between its CARD, PHD1, and CTT domains.

bioRxiv · Oct 23, 2023Cell Biology

The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer

A. Armaos, F. Serra, I. Nunez Carpintero, J. H. Seo, S. C. Baca, S. Gustincich, A. Valencia, M. L. Freedman, D. Cirillo, C. Giambartolomei, G. G. Tartaglia

PENGUIN reconstructs protein interactions at enhancer-promoter regions and identifies cancer-associated SNPs in prostate cancer cell lines.

bioRxiv · Oct 20, 2022Cancer Biology

Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes

N. De Sarkar, R. D. Patton, A.-L. Doebley, B. Hanratty, A. J. Kreitzman, J. F. Sarthy, M. Ko, M. Adil, S. Brahma, M. P. Meers, D. H. Janssens, L. S. Ang, I. Coleman, A. Bose, R. F. Dumpit, , G. Ha

This paper identifies nucleosome patterns in ctDNA that distinguish advanced prostate cancer phenotypes, achieving high accuracy in classification using a prediction model.

bioRxiv · Jun 21, 2022Cancer Biology

HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming

X. Lu, K. W. Fong, G. Gritsina, F. Wang, S. C. Baca, J. Berchuck, J. Ross, E. Corey, W. Catalona, N. S. Chandel, X. Yang, M. L. Freedman, J. C. Zhao, J. Yu

This study identifies HOXB13's AR-independent role in suppressing lipogenesis via HDAC3-mediated epigenetic repression, linking its loss to metastatic prostate cancer progression.

bioRxiv · Oct 4, 2021Cancer Biology

CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapies

J. H. Hwang, R. Arafeh, J.-H. Seo, S. C. Baca, M. Ludwig, T. E. Arnoff, C. Richter, H. E. Bergom, S. McSweeney, J. P. Rennhack, S. A. Klingenberg, A. T. Cheung, J. Kwon, J. So, S. Kregel, , W. Hahn

This study identifies CREB5 as a key driver of resistance to androgen receptor targeting therapies by reprogramming nuclear interactions and activating TGFβ and Wnt signaling pathways.

bioRxiv · Aug 18, 2021Cancer Biology

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

S. C. Baca, D. Y. Takeda, J.-H. Seo, J. Hwang, S. Y. Ku, R. Arafeh, T. Arnoff, S. Agarwal, C. Bell, E. O'Connor, X. Qiu, S. Abu Alaiwi, R. I. Corona, M. A. S. Fonseca, C. Giambartolomei, , M. L. Freedman

The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.

bioRxiv · Oct 23, 2020Cancer Biology

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

bioRxiv · Aug 8, 2019 · PreprintCancer Biology